Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Robert Califf Likely To Find Many Familiar Problems Upon His Return To US FDA

Nov 12 2021

• By Derrick Gingery

Food and Drug Administration Commissioner nominee Doctor Robert Califf testifies at his nomination hearing at the Senate Health, Education, Labor and Pensions Committee on Capitol Hill in Washington, November 17, 2015. REUTERS/Gary Cameron — • Source: Reuters/Gary Cameron

Related Content

US FDA Adcomm Modernization Includes How Meetings Are Scheduled

Aug 17 2021

Power To The (Adcomm) People: Members Believe Votes Should More Directly Affect US FDA Decisions

Aug 17 2021

Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews

Aug 01 2017

USPTO Faces Growing Pressure To Enter Battle Over Drug Pricing

Sep 24 2021

GDUFA III Talks Completed; Fees will Fund Inspection, Complex Generic Improvements

Sep 02 2021

GDUFA III: Convening Enhanced Mid-Cycle Meeting Will Cost Sponsors

Oct 30 2021

FDA Chief Counsel Stacy Cline Amin Guided Agency Through COVID-19 EUAs And Guidances

Jan 12 2021

US FDA’s Stein ‘Excited’ About Real-World Evidence, Rare Disease Endpoint Pilot Programs

Sep 15 2021

Opioid Blister Packs Need Study Before Mandate, Groups Urge

Aug 12 2019

Califf Lowering FDA Drawbridge To Work With External Expertise

Apr 18 2016

FDA Chief Scientist Post A Chance For Califf To Make Mark

Sep 01 2016

Califf Maintains Desire To Stay At FDA, But Would Either Presidential Candidate Keep Him?

Nov 05 2016

Political Appointees Shouldn't Influence Approval Decisions, Califf Says

Oct 20 2016

Accelerated Approval Should Be Less 'Wide Open,' Califf Says

Oct 20 2016

FDA's Opioid Regret? Skipping Another Zohydro Meeting, Califf Says

Mar 03 2016

EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review

Aug 30 2016

The End Of Small Molecule Drugs? Potential Implications Of US Price ‘Negotiation’

Nov 06 2021

US FDA Chief Scientist Hinton’s Departure Leaves Vacancy Atop Makena Decision Tree

Nov 01 2021

Pfizer COVID-19 Vaccine Trial Diversity Slips As Enrollment Rises, Unlike Moderna

Sep 18 2020

US FDA Advisory Committees Could Get Revamp With A Focus On Science Over Emotion

Jun 16 2021

US FDA Lowers FY '22 PDUFA Fees Due to Hiring, Attrition Concerns

Aug 13 2021

Dsuvia Gets Warning Letter As US FDA’s Opioid Decisions Complicate Commissioner Race

Feb 17 2021

US FDA’s Top Two Vaccine Officials Announce Surprise Retirements

Sep 01 2021

PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals

Aug 23 2021

Beyond Aduhelm: OIG Review Will Put FDA’s Entire Accelerated Approval Program Under Microscope

Aug 05 2021

US FDA’s COVID Master Protocol Guidance To Maintain Influence Post-Pandemic

May 17 2021

US FDA's Califf On Real-World Evidence: 'Use It For The Right Purposes'

Jun 21 2016

Teva Launches Generic EpiPen At Same Price As Mylan's Generic

Nov 27 2018

Related Companies

Mylan Pharmaceuticals Inc.

Viatris Inc.

Teva Pharmaceutical Industries Ltd.

Biogen, Inc.

Eisai Co., Ltd.

Verily

Talphera, Inc.

Zogenix, Inc.

Additional Topics

United States FDA Leadership Regulation BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window